Oxurion NV (TG40) Stock Price & Analysis

3 Followers

TG40 Stock Chart & Stats

€0.02€0.00(0.00%)

At close: Aug 27 2:00 AM GMT+2

Day’s Range: EUR 0.02 - EUR 0.02
52-Week Range: EUR 0.01 - EUR 1.13
Previous Close: EUR 0.02
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 185.60K
Enterprise Value: EUR 11.92M
Total Cash (Recent Filing): EUR 455.00K
Total Debt (Recent Filing): EUR 11.33M
Price to Earnings (P/E): ―
Beta: -0.67
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Oxurion NV News

Atlas Special Opportunities II Cuts Oxurion Stake Below 10%

The latest announcement is out from Oxurion NV ( ($GB:0G99) ). Oxurion NV, headquartered in Leuven and listed on Euronext Brussels, is building a technology-enabled clinical research and software platform.

6d agoTG40 0G99

Oxurion Reports Atlas Stake Drop Below 20% Threshold

Oxurion NV ( ($GB:0G99) ) has issued an announcement. Oxurion NV has reported a change in its shareholder base following a transparency notification under Belgian disclosure rules. Atlas Special Opportunities

2w agoTG40 0G99

Atlas Rebuilds Major Stake in Oxurion After Fully Exiting Position

Oxurion NV ( ($GB:0G99) ) has issued an announcement. Oxurion NV has received two transparency notifications from Atlas Special Opportunities II LLC under Belgian disclosure rules, highlighting rapid shifts in

4w agoTG40 0G99

Key Investors Cut Stakes in Oxurion as Transparency Filings Reveal Exit

Oxurion NV ( ($GB:0G99) ) has issued an announcement. Oxurion NV reported several transparency notifications under Belgian disclosure rules, indicating significant changes in shareholdings by Market Wizards B.V. and Atlas

1M agoTG40 0G99

Market Wizards B.V. Crosses 3% Ownership Threshold in Oxurion NV

An announcement from Oxurion NV ( ($GB:0G99) ) is now available. Market Wizards B.V. has notified Oxurion NV that its stake in the company has crossed the 3% threshold under

1M agoTG40 0G99

Oxurion expands share base after Atlas bond conversion boosts capital

An update from Oxurion NV ( ($GB:0G99) ) is now available. Oxurion NV has announced a capital increase of EUR 50,000 following the conversion of two convertible bonds by Atlas

1M agoTG40 0G99

Oxurion Publishes Regulated Half-Year 2026 Financial Update

The latest announcement is out from Oxurion NV ( ($GB:0G99) ). Oxurion NV, headquartered in Leuven and traded on Euronext Brussels, released its financial and business update for the six-month

1M agoTG40 0G99

Oxurion Reports Major Shifts in Shareholder Stakes Under Belgian Transparency Rules

The latest announcement is out from Oxurion NV ( ($GB:0G99) ). Oxurion NV has disclosed several changes in major shareholdings under Belgian transparency rules, highlighting shifting positions among key financial

1M agoTG40 0G99

Oxurion Moves to Acquire Eclevar, Expanding into MedTech CRO Market

Oxurion NV ( ($GB:0G99) ) has provided an update. Oxurion NV has entered exclusive negotiations to acquire the activities and operational assets of French MedTech specialist CRO Eclevar for a

1M agoTG40 0G99

Oxurion boosts capital as Atlas converts bonds, expanding share base

Oxurion NV ( ($GB:0G99) ) has issued an update. Oxurion has announced a capital increase of EUR 75,000 following the conversion of three convertible bonds by Atlas Special Opportunities, part

1M agoTG40 0G99

TG40 FAQ

What was Oxurion NV’s price range in the past 12 months?

Oxurion NV lowest stock price was €0.01 and its highest was €1.13 in the past 12 months.

What is Oxurion NV’s market cap?

Oxurion NV’s market cap is €185.60K.

When is Oxurion NV’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Oxurion NV’s earnings last quarter?

Oxurion NV released its earnings results on Sep 03, 2026. The company reported -€0.01 earnings per share for the quarter.

Is Oxurion NV overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Oxurion NV pay dividends?

Oxurion NV does not currently pay dividends.

What is Oxurion NV’s EPS estimate?

Oxurion NV’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Oxurion NV have?

Oxurion NV has 232,004,730 shares outstanding.

What happened to Oxurion NV’s price movement after its last earnings report?

Oxurion NV reported an EPS of -€0.01 in its last earnings report. Following the earnings report the stock price went down -4.348%.

Which hedge fund is a major shareholder of Oxurion NV?

Currently, no hedge funds are holding shares in DE:TG40

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Oxurion NV

Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.

Oxurion NV (TG40) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	3	2	17
Technical Analysis	3	2	5
Moving Averages	0	0	12

Technical Analysis >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

TG40 Stock Chart & Stats

Oxurion NV News

Atlas Special Opportunities II Cuts Oxurion Stake Below 10%

Oxurion Reports Atlas Stake Drop Below 20% Threshold

Atlas Rebuilds Major Stake in Oxurion After Fully Exiting Position

Key Investors Cut Stakes in Oxurion as Transparency Filings Reveal Exit

Market Wizards B.V. Crosses 3% Ownership Threshold in Oxurion NV

Oxurion expands share base after Atlas bond conversion boosts capital

Oxurion Publishes Regulated Half-Year 2026 Financial Update

Oxurion Reports Major Shifts in Shareholder Stakes Under Belgian Transparency Rules

Oxurion Moves to Acquire Eclevar, Expanding into MedTech CRO Market

Oxurion boosts capital as Atlas converts bonds, expanding share base

TG40 FAQ

Company Description

Oxurion NV

Oxurion NV (TG40) Earnings & Revenues

Technical Analysis

Overall Consensus

Popular Stocks

Become an Expert with TipRanks Premium